News from janssen therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 21, 2017, 17:06 ET Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved...


Oct 25, 2016, 08:00 ET Janssen Therapeutics Announces Funding in Support of Improved Retention in Care and Access to Treatment for Blacks and African Americans Living with HIV in Southern United States and other Rural Areas

Janssen Therapeutics* announced today the recipients of funding from a special Request for Applications (RFA) to encourage comprehensive...


Jul 18, 2016, 08:00 ET U.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved an...


Mar 21, 2016, 05:00 ET Janssen Therapeutics Announces Funding for Organizations Focused on Improving Care and Treatment for Vulnerable Populations Living with HIV

Janssen today announced the recipients of funding from two special Requests for Applications (RFA) to encourage innovative models of care and support ...


Sep 08, 2015, 08:00 ET Your Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV Community Organizations

Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of people living with HIV said they give advice or tell...


Jul 23, 2015, 05:43 ET Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the ...


May 21, 2015, 08:00 ET PREZCOBIX™ (darunavir/cobicistat) aprobado en EE. UU. para el tratamiento de adultos que viven con VIH-1

Janssen Therapeutics, una División de Janssen Products, LP (Janssen), anunció hoy que la Administración de Alimentos y Medicamentos (Food and Drug...


Apr 01, 2015, 08:00 ET Janssen Therapeutics Announces Support for Organizations Focused on Improving Care and Treatment for People Who Inject Drugs Living with HIV and/or Hepatitis C

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the recipients of funding from a special request for applications...


Jan 29, 2015, 04:17 ET PREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of Adults Living With HIV-1

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ ...


Nov 05, 2014, 04:48 ET OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection

Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO®...


Nov 25, 2013, 05:00 ET VIDEO NOW AVAILABLE: OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO™...


Nov 22, 2013, 08:25 ET OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO™...


Jul 16, 2013, 08:30 ET Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students

Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced today the recipient of the second scholarship the company is supporting...


May 30, 2013, 10:00 ET Survey of Participants from Landmark GRACE Trial Provides Patients' Perspectives from an HIV Clinical Study

A survey of a segment of clinical trial participants from the GRACE (Gender, Race And Clinical Experience) trial, the largest-ever study of...


Apr 24, 2013, 08:06 ET Janssen Therapeutics LINCC™ Program Continues its Commitment to Underserved Populations with Charitable Contributions to 16 HIV/AIDS Organizations Across the U.S.

Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from its...


Dec 31, 2012, 09:00 ET FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis

Janssen Therapeutics, Division of Janssen Products, LP, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval...


Dec 10, 2012, 04:01 ET FDA Approves Prescribing Information Update for EDURANT® (rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing...


Nov 09, 2012, 05:01 ET FDA Approves New 800mg PREZISTA® (darunavir) Tablet

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved a new 800mg tablet...


Jul 23, 2012, 08:30 ET Award-Winning Documentary, The Other City, Returns to Washington, D.C. for AIDS 2012

Women, youth and healthcare disparities are among the HIV community topics that will be discussed at screenings of the documentary film The Other...


May 29, 2012, 09:00 ET FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has issued a Complete Response...


Apr 24, 2012, 09:24 ET Watching, Reading and Listening: A New Way to Interact with Patient Information

It lies within the compact folded rectangle that accompanies prescription medicines. In black and white on paper, it follows prescription medicine...


Apr 12, 2012, 09:00 ET Janssen Therapeutics Establishes Point Scholarship for LGBT Students

Janssen Therapeutics, Division of Janssen Products, LP, is supporting education for lesbian, gay, bisexual and transgender (LGBT) students through...


Mar 27, 2012, 08:00 ET FDA Approves INTELENCE® (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1, Following Priority Review

Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved INTELENCE®...


Jan 05, 2012, 08:00 ET Janssen Therapeutics Announces Latest Recipients of LINCC™ Funding Initiative

Janssen Therapeutics, Division of Janssen Products, LP, today announced the funding recipients of the Linking In-Need Communities to Care Initiative™ ...


Aug 01, 2011, 09:00 ET Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds

Social stigma is the largest barrier to routine HIV testing by African-American frontline care physicians, according to a survey commissioned by...